Texas Biotechnology (TXB) - 500 Beiträge pro Seite
eröffnet am 23.05.00 22:26:43 von
neuester Beitrag 29.07.02 23:15:24 von
neuester Beitrag 29.07.02 23:15:24 von
Beiträge: 47
ID: 142.865
ID: 142.865
Aufrufe heute: 0
Gesamt: 2.047
Gesamt: 2.047
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 8598 | |
| vor 58 Minuten | 7313 | |
| heute 18:18 | 3919 | |
| heute 14:42 | 3585 | |
| vor 57 Minuten | 2161 | |
| heute 18:25 | 2012 | |
| heute 17:54 | 1916 | |
| vor 1 Stunde | 1825 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.423,31 | +1,13 | 301 | |||
| 2. | 3. | 165,36 | -3,43 | 131 | |||
| 3. | 2. | 10,320 | -2,46 | 99 | |||
| 4. | 6. | 6,8420 | -1,13 | 62 | |||
| 5. | 8. | 6,7120 | -1,27 | 60 | |||
| 6. | 13. | 0,1990 | +1,53 | 54 | |||
| 7. | Neu! | 11,583 | -7,10 | 51 | |||
| 8. | 4. | 1,1200 | -12,50 | 46 |
Feedback
Die Aktie dürfte einigen von euch bekannt sein. Sie war nämlich in der im Aktionär enthaltenen Leseprobe des Global Biotech Investors enthalten.
Einige Auszüge: „ TXB steht unmittelbar vor der Ertragsphase! Die Geselschaft forscht an neuen Wirkstoffen zur Behandlung von Gefässkrankheiten. Mit Novastan steht TXB kurz vor der Zulassung des 1. Medikamentes des Unternehmens. Schon jetzt ist bekannt, dass die US-Gesundheitsbehörde FDA unter gewissen Auflagen die Zulassung für Novastan erteilen wird (s. unten). Novastan vermeidet eine mögliche Abwehrreaktion des Immunsystems bei der Einnamhe von Heparin. Heparin wird bei ca. 5 Mio Patienten in den USA zur Hemmung von Thrombosen verabreicht. Novastan wurde in Zusammenarbeit mit SmithKline Beecham entwickelt. SmithKline Beecham wird das Medikament auch vermarkten.
Neben diesem ersten marktreifen Produkt gibt es noch 2 Produkte in Phase II, die die weitere Zukunft von TXB sichern:
Endothelin Receptor Antagonist (TBC11251)
Endothelins are a family of potent vasoconstrictive peptides that have been shown to play a critical role in the control of blood flow. Regulation of endothelin action has been shown to improve hemodynamics in patients with congestive heart failure, a condition estimated to affect up to 5 million people in the U.S. Other diseases where endothelin has been implicated are hypertension, subarachnoid hemorrhage, and prostate cancer.
Selectin Antagonist (TBC1269)
Selectins are a family of proteins that play a key role in the earliest stages of the inflammatory process by mediating the cellular adhesion of white blood cells to the vascular wall. This adhesion enables white blood cells to migrate into areas and release substances which cause inflammation.
weiteres unter http://www.tbc.com/clinical.html !
Zahlen vom 1.Quartal und wichtige News:
Revenues for the first quarter of 2000 totaled $523,000, compared to $535,000 for the same quarter in 1999. Operating expenses were $5,713,000 for the first quarter of 2000, compared to $4,498,000 for the same quarter of 1999. The increase was due primarily to increased clinical trial expenses related to the development of sitaxsentan for pulmonary hypertension and for pre-marketing programs for NOVASTAN®(argatroban). Net loss, basic and diluted for the first quarter of 2000, was $4,987,000, or $0.14 per share compared to a net loss, basic and diluted, of $3,579,000, or $0.10 per share for the first quarter of 1999.
Cash, cash equivalents and short-term investments were $14.4 million at March 31, 2000. In April 2000, TBC raised approximately $65.0 million from a public offering of our common stock.
Update on NOVASTAN (argatroban)
TBC announced that it has submitted its response to the approvable letter for NOVASTAN issued by the U.S. Food & Drug Administration on February 18, 2000. The approvable letter from FDA included the Agency`s recommendation for NOVASTAN as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Based on recent discussions with representatives from FDA, TBC expects a response from the Agency by mid July.
Management also reported that SmithKline Beecham (SB), the partner for the manufacturing and marketing of NOVASTAN in the U.S. and Canada, and TBC are re-branding the product to avoid confusion with several other approved hospital based drugs.
TBC also reported that it has filed a Canadian New Drug Submission seeking approval for argatroban in Canada as treatment for HIT. The Therapeutic Products Program, the Canadian equivalent of the FDA, classified the argatroban submission as a priority review, and is expected to issue its formal response in the second half of this year.
Update on sitaxsentan, TBC`s lead endothelin antagonist
During the first quarter, TBC completed enrollment of a 20 patient open- label Phase II clinical trial to assess the safety and tolerability of sitaxsentan in patients with pulmonary hypertension (PH). Preliminary results for the trial will be available in the third quarter of this year.
A Phase IIb/III clinical trial is currently being finalized with our Scientific Advisory Board and is expected to be initiated during the second half of this year. To date, sitaxsentan has demonstrated statistically significant results in Phase II clinical trials for chronic heart failure and essential hypertension. TBC is currently focused on developing the product as a treatment for PH. At this time, there are no orally available drugs approved for PH and there is a significant unmet medical need for a safe, well-tolerated and effective oral therapy for these patients.
Update on VLA-4 Program
Also during the first quarter, Texas Biotechnology scientists presented data on the Company`s VLA-4 (very late antigen-4) antagonist research program at the American Chemical Society 219th National Meeting, March 2000. VLA-4 antagonists represent a new class of compounds that have demonstrated significant activity in several well-accepted in vivo models involving arthritis and lung inflammation.
The three Texas Biotechnology presentations included an oral presentation on TBC3486: Novel, Highly Potent and Selective VLA-4 Antagonist and two poster presentations: Novel Urea Analogs that are Potent VLA-4 Antagonists (Ronald J. Biediger, Ph.D., et al) and Novel N,N-Disubstituted Amides that are Highly Potent VLA-4 Antagonists (Jamal M. Kasier, Ph.D., et al).
VLA-4, also referred to as the integrin alpha4beta1, is found on most types of white blood cells and plays a key role in inflammation by binding to VCAM-1. VCAM-1 is a member of the family of proteins called cell adhesion molecules that are also known to be involved in the inflammatory response and cause white blood cells to migrate to sites of inflammation on the walls of blood vessels. TBC scientists believe that by blocking the action of certain cell adhesion molecules, in this case VCAM-1, these compounds may prevent inflammation in a highly specific manner. Currently, over twenty-nine million people in the United States suffer from inflammatory diseases.
Texas Biotechnology is a biopharmaceutical company focused on the development and commercialization of small molecule drugs to treat a variety of diseases including thrombosis, pulmonary hypertension, heart failure and asthma.
This press release contains forward-looking information that is subject to certain risks; trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are attainment of research and clinical goals of product candidates, attainment of required governmental approval and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission.
Fazit: Beim Verlust lagen die Zahlen unter den ERwartungen. Ob dies allerdings relevant ist, dürfte bezweifelt werden, da es es sich lediglich um erhöhte MArketingkosten handelt.
Leider gibt es noch keine neuen ANalysteneinschätzungen nach den Zahlen.
Aber angesichts der obigen zahlreichen positiven News und der bevorstehenden Produkteinführung sollte der Wert mindestens beobachtet werden, da etwa die Analysten von Paine Webber in den Jahren 2001 von 0,65$ und im Jahre von 1.08$ Gewinn ausgehen, was bei einem Kurs von aktuell unter 12$ sehr preiswert erscheint!
Einige Auszüge: „ TXB steht unmittelbar vor der Ertragsphase! Die Geselschaft forscht an neuen Wirkstoffen zur Behandlung von Gefässkrankheiten. Mit Novastan steht TXB kurz vor der Zulassung des 1. Medikamentes des Unternehmens. Schon jetzt ist bekannt, dass die US-Gesundheitsbehörde FDA unter gewissen Auflagen die Zulassung für Novastan erteilen wird (s. unten). Novastan vermeidet eine mögliche Abwehrreaktion des Immunsystems bei der Einnamhe von Heparin. Heparin wird bei ca. 5 Mio Patienten in den USA zur Hemmung von Thrombosen verabreicht. Novastan wurde in Zusammenarbeit mit SmithKline Beecham entwickelt. SmithKline Beecham wird das Medikament auch vermarkten.
Neben diesem ersten marktreifen Produkt gibt es noch 2 Produkte in Phase II, die die weitere Zukunft von TXB sichern:
Endothelin Receptor Antagonist (TBC11251)
Endothelins are a family of potent vasoconstrictive peptides that have been shown to play a critical role in the control of blood flow. Regulation of endothelin action has been shown to improve hemodynamics in patients with congestive heart failure, a condition estimated to affect up to 5 million people in the U.S. Other diseases where endothelin has been implicated are hypertension, subarachnoid hemorrhage, and prostate cancer.
Selectin Antagonist (TBC1269)
Selectins are a family of proteins that play a key role in the earliest stages of the inflammatory process by mediating the cellular adhesion of white blood cells to the vascular wall. This adhesion enables white blood cells to migrate into areas and release substances which cause inflammation.
weiteres unter http://www.tbc.com/clinical.html !
Zahlen vom 1.Quartal und wichtige News:
Revenues for the first quarter of 2000 totaled $523,000, compared to $535,000 for the same quarter in 1999. Operating expenses were $5,713,000 for the first quarter of 2000, compared to $4,498,000 for the same quarter of 1999. The increase was due primarily to increased clinical trial expenses related to the development of sitaxsentan for pulmonary hypertension and for pre-marketing programs for NOVASTAN®(argatroban). Net loss, basic and diluted for the first quarter of 2000, was $4,987,000, or $0.14 per share compared to a net loss, basic and diluted, of $3,579,000, or $0.10 per share for the first quarter of 1999.
Cash, cash equivalents and short-term investments were $14.4 million at March 31, 2000. In April 2000, TBC raised approximately $65.0 million from a public offering of our common stock.
Update on NOVASTAN (argatroban)
TBC announced that it has submitted its response to the approvable letter for NOVASTAN issued by the U.S. Food & Drug Administration on February 18, 2000. The approvable letter from FDA included the Agency`s recommendation for NOVASTAN as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Based on recent discussions with representatives from FDA, TBC expects a response from the Agency by mid July.
Management also reported that SmithKline Beecham (SB), the partner for the manufacturing and marketing of NOVASTAN in the U.S. and Canada, and TBC are re-branding the product to avoid confusion with several other approved hospital based drugs.
TBC also reported that it has filed a Canadian New Drug Submission seeking approval for argatroban in Canada as treatment for HIT. The Therapeutic Products Program, the Canadian equivalent of the FDA, classified the argatroban submission as a priority review, and is expected to issue its formal response in the second half of this year.
Update on sitaxsentan, TBC`s lead endothelin antagonist
During the first quarter, TBC completed enrollment of a 20 patient open- label Phase II clinical trial to assess the safety and tolerability of sitaxsentan in patients with pulmonary hypertension (PH). Preliminary results for the trial will be available in the third quarter of this year.
A Phase IIb/III clinical trial is currently being finalized with our Scientific Advisory Board and is expected to be initiated during the second half of this year. To date, sitaxsentan has demonstrated statistically significant results in Phase II clinical trials for chronic heart failure and essential hypertension. TBC is currently focused on developing the product as a treatment for PH. At this time, there are no orally available drugs approved for PH and there is a significant unmet medical need for a safe, well-tolerated and effective oral therapy for these patients.
Update on VLA-4 Program
Also during the first quarter, Texas Biotechnology scientists presented data on the Company`s VLA-4 (very late antigen-4) antagonist research program at the American Chemical Society 219th National Meeting, March 2000. VLA-4 antagonists represent a new class of compounds that have demonstrated significant activity in several well-accepted in vivo models involving arthritis and lung inflammation.
The three Texas Biotechnology presentations included an oral presentation on TBC3486: Novel, Highly Potent and Selective VLA-4 Antagonist and two poster presentations: Novel Urea Analogs that are Potent VLA-4 Antagonists (Ronald J. Biediger, Ph.D., et al) and Novel N,N-Disubstituted Amides that are Highly Potent VLA-4 Antagonists (Jamal M. Kasier, Ph.D., et al).
VLA-4, also referred to as the integrin alpha4beta1, is found on most types of white blood cells and plays a key role in inflammation by binding to VCAM-1. VCAM-1 is a member of the family of proteins called cell adhesion molecules that are also known to be involved in the inflammatory response and cause white blood cells to migrate to sites of inflammation on the walls of blood vessels. TBC scientists believe that by blocking the action of certain cell adhesion molecules, in this case VCAM-1, these compounds may prevent inflammation in a highly specific manner. Currently, over twenty-nine million people in the United States suffer from inflammatory diseases.
Texas Biotechnology is a biopharmaceutical company focused on the development and commercialization of small molecule drugs to treat a variety of diseases including thrombosis, pulmonary hypertension, heart failure and asthma.
This press release contains forward-looking information that is subject to certain risks; trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are attainment of research and clinical goals of product candidates, attainment of required governmental approval and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission.
Fazit: Beim Verlust lagen die Zahlen unter den ERwartungen. Ob dies allerdings relevant ist, dürfte bezweifelt werden, da es es sich lediglich um erhöhte MArketingkosten handelt.
Leider gibt es noch keine neuen ANalysteneinschätzungen nach den Zahlen.
Aber angesichts der obigen zahlreichen positiven News und der bevorstehenden Produkteinführung sollte der Wert mindestens beobachtet werden, da etwa die Analysten von Paine Webber in den Jahren 2001 von 0,65$ und im Jahre von 1.08$ Gewinn ausgehen, was bei einem Kurs von aktuell unter 12$ sehr preiswert erscheint!
Market Cap: $ 443,171,250
ISt das nicht mal wieder typisch Deutsch?
Alle wollen immer dick Kohle verdienen; wenn ich mir aber mal die Mühe machen, einen potentiellen Highflyer vorzustellen, reagieren die Deutschen mit Ignoranz.
Nun gut, vielleicht etwas übertrieben, da es schon etwas spät ist, aber ich hoffe doch, dass morgen einige hier ihre MEinung abgeben, aber nicht üner dieses Posting, sondern über TXB!!!!
Da es heute ein SCheiß Tag war, schon ich mir nochmals die am Sonntag erfolgte Rückkehr des Totengräbers an!!
Alle wollen immer dick Kohle verdienen; wenn ich mir aber mal die Mühe machen, einen potentiellen Highflyer vorzustellen, reagieren die Deutschen mit Ignoranz.
Nun gut, vielleicht etwas übertrieben, da es schon etwas spät ist, aber ich hoffe doch, dass morgen einige hier ihre MEinung abgeben, aber nicht üner dieses Posting, sondern über TXB!!!!
Da es heute ein SCheiß Tag war, schon ich mir nochmals die am Sonntag erfolgte Rückkehr des Totengräbers an!!
Nett,daß du texas mal vorstellst.Ich bin da aber etwas pessimistischer:Novastan soll demnächst zugelassen werden.Was wenn nicht?
Dann gehts runter!!Novastan ist nämlich das erste Medikament von texas bio.Alle Gewinnschätzungen begründen sich auf Novastan.
Außerdem:Erst in 2002 soll ein Gewinn von 1.08 je Aktie erzielt werden.Alles hängt von der Zulassung und dem Markterfolg eines Wikstoffes ab.
Die Chance ist groß,aber das Risiko lassen die meisten Analysten unter den Tisch fallen.Wenn du auf Biotech setzen willst,dann solltest
du größere Werte,mit mehr (poteziellen)Wirkstoffen kaufen.Meine Tipps sind da Millennium Pharmaceuticals (konservativ)und Medarex(spekulativ).
Stell doch noch ein paar andere Biotechs vor.
Tolpan
Dann gehts runter!!Novastan ist nämlich das erste Medikament von texas bio.Alle Gewinnschätzungen begründen sich auf Novastan.
Außerdem:Erst in 2002 soll ein Gewinn von 1.08 je Aktie erzielt werden.Alles hängt von der Zulassung und dem Markterfolg eines Wikstoffes ab.
Die Chance ist groß,aber das Risiko lassen die meisten Analysten unter den Tisch fallen.Wenn du auf Biotech setzen willst,dann solltest
du größere Werte,mit mehr (poteziellen)Wirkstoffen kaufen.Meine Tipps sind da Millennium Pharmaceuticals (konservativ)und Medarex(spekulativ).
Stell doch noch ein paar andere Biotechs vor.
Tolpan
Hallo,
natürlich ist klar, dass TXB ein kleines spekulatives INvestment ist, was man schon an der Marktkapitakisierung sieht.
Ich meine auch, dass die Abhängigkeit von Novastan aus dem Posting bereits ersichtlci ist, da ja sowieso kleines Biotechs meist von 1 Medikament abhängen.
Generell bin ich auch deiner Meinung, im Wesentlichen in Große Werte zu investieren, was ich auch schon mehrfach gepostet habe. Ich habe selbst HGSI, AFFX, MLNM, MEDX und PDLI.
Das Posting dient auch in erster Linie zur Informationsgestaltung und stellt auch keine direkte Kaufempfehlung dar.
Ich beschäftige mich aber gern etwas genauer mit der Matrie, in die ich investiere, und dazu gehören eben auch kleine Unternehmen wie TXB.
noch zu TXB: per 31.März besaß mann nur noch 14 Mio $ Cash.
Allerdings wurden im April durch eine Kapitalerhöhung 65 Mio $ in die Kassen gespült, so dass jetzt wieder ausreichend Liquidität vorhanden ist.
natürlich ist klar, dass TXB ein kleines spekulatives INvestment ist, was man schon an der Marktkapitakisierung sieht.
Ich meine auch, dass die Abhängigkeit von Novastan aus dem Posting bereits ersichtlci ist, da ja sowieso kleines Biotechs meist von 1 Medikament abhängen.
Generell bin ich auch deiner Meinung, im Wesentlichen in Große Werte zu investieren, was ich auch schon mehrfach gepostet habe. Ich habe selbst HGSI, AFFX, MLNM, MEDX und PDLI.
Das Posting dient auch in erster Linie zur Informationsgestaltung und stellt auch keine direkte Kaufempfehlung dar.
Ich beschäftige mich aber gern etwas genauer mit der Matrie, in die ich investiere, und dazu gehören eben auch kleine Unternehmen wie TXB.
noch zu TXB: per 31.März besaß mann nur noch 14 Mio $ Cash.
Allerdings wurden im April durch eine Kapitalerhöhung 65 Mio $ in die Kassen gespült, so dass jetzt wieder ausreichend Liquidität vorhanden ist.
Trading Spotlight
Da einige hier TXB- interssiert sind, hole ich den THread mal rauf, damit ihr ihn weiterführen könnt.
Obige Ergebnisschätzungen sind dem GBI entnommen.
TXB ist auch so ein Kanditat, der vielleicht mal in 1 Jahr ein Highflyer wird.
Viel SPass beim diskutieren
Obige Ergebnisschätzungen sind dem GBI entnommen.
TXB ist auch so ein Kanditat, der vielleicht mal in 1 Jahr ein Highflyer wird.
Viel SPass beim diskutieren
es gibt ja einige TXB-Fans hier
THread um weiterführen
THread um weiterführen
TXB läuft bereits 
aktueller Marktwert: 650 Mio $
ex Yahoo-Board:
TXB: FDA FINAL APPROPAL within 30 days
by: ericgrop 6/21/00 3:53 pm
Msg: 17709 of 17726
TXB: FDA FINAL APPROPAL within 30 days are 28+
1) PAINEWEBBER ($35 12 months)
2) PRUDENTIAL VECTOR ($25-29 2 months)
3) KERCHEVILLE & CO. ($25-29 2 months as of 2 months ago)
TXB: FDA FINAL APPROPAL within 30 days
by: ericgrop 6/21/00 3:53 pm
Msg: 17709 of 17726
TXB: FDA FINAL APPROPAL within 30 days are 28+
1) PAINEWEBBER ($35 12 months)
2) PRUDENTIAL VECTOR ($25-29 2 months)
3) KERCHEVILLE & CO. ($25-29 2 months as of 2 months ago)
nochmal, die Zulassung für Novastan seitens der FDA steht unmitelbar bevor. Dies könnte den Kurs weiter beflügeln!
Gehe jetzt ins Bett und beende diesen frühen Morgen mit meinem 1000.Posting hier bei WO !
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
First Union Strong Buy Recommendation
First Union issued a "Strong Buy" on TXB this morning with a price target of $30. I saw the release on Bloomberg.
First Union issued a "Strong Buy" on TXB this morning with a price target of $30. I saw the release on Bloomberg.
TXB Astham Fantasie?
Lt. Gerücht im RB Board geht der gestrige Kursanstieg nicht auf die obige Kaufempfehlung zurück als vielemhr auf Gerüchte, dass es bald ein Kopoperation innnerhalb der nächsten 2 Monate bezüglich TXB´s Asthma Medikament geben wird.
ZUdem wird mit der Zulassung von Novastan Ende Juli gerechnet.
Der CHart sieht zudem vielversprechend aus
Lt. Gerücht im RB Board geht der gestrige Kursanstieg nicht auf die obige Kaufempfehlung zurück als vielemhr auf Gerüchte, dass es bald ein Kopoperation innnerhalb der nächsten 2 Monate bezüglich TXB´s Asthma Medikament geben wird.
ZUdem wird mit der Zulassung von Novastan Ende Juli gerechnet.
Der CHart sieht zudem vielversprechend aus
Bin auch schon einige Tage dabei.denke sogar das wir nach kurzem Luft holen(Gewinn mitnahmen)die 30Euro noch sehen werden.Hätte texas wegen eines blöden Stopps bei 13,50 schon beinahe verloren.sie viel vor kurzem schon einmal an einem tag 1-1,40Euro,dann ging es wieder aufwärts.Halte zur zeit noch zwei kleine Biotech Werte Creativ biom. WKN885393 und Nanophase WKN910885 von denen ich mir auch ne kleine(grosse?)Rally verspreche.Hatte bei beiden eine sehr gute Performenc die letzten Tage.Euere Meinungen bitte.
möchte hier noch mal die BEdeutung des ICOS-Deals von ANfang Juni aufzeigen:
Icos, Texas Biotech to collaborate on drug group
NEW YORK, June 6 (Reuters) - ICOS Corp. (NasdaqNM:ICOS - news) and Texas Biotechnology Corp. (AMEX:TXB - news) said on Tuesday they are forming a joint venture to develop and commercialize endothelin-A receptor antagonists, a class of drugs to treat hypertension, heart failure and prostate cancer.
The immediate focus of the joint venture will be to initiate a Phase IIb/III pulmonary hypertension trial for sitaxsentan (TBC11251), continue clinical development for sitaxsentan in chronic heart failure, and explore applications for second generation endothelin antagonists including TBC3711.
Both parties will equally fund the cost of research and development of sitaxsentan and second-generation endothelin antagonist compounds, commercialize resulting products, and share equally in the profits from this worldwide collaboration.
ICOS will make milestone payments to Texas Biotechnology that could be as much as $55.5 million for the development and commercialization of products resulting from the collaboration.
``The most compelling finding we saw with sitaxsentan was its ability to reduce pulmonary pressures without negatively affecting a patient`s heart rate or their systemic pressures,`` Dr. Wilson Colucci, professor of Medicine and Chief of Cardiovascular Medicine at Boston University and principal investigator for the Phase II chronic heart failure trial.
Icos, Texas Biotech to collaborate on drug group
NEW YORK, June 6 (Reuters) - ICOS Corp. (NasdaqNM:ICOS - news) and Texas Biotechnology Corp. (AMEX:TXB - news) said on Tuesday they are forming a joint venture to develop and commercialize endothelin-A receptor antagonists, a class of drugs to treat hypertension, heart failure and prostate cancer.
The immediate focus of the joint venture will be to initiate a Phase IIb/III pulmonary hypertension trial for sitaxsentan (TBC11251), continue clinical development for sitaxsentan in chronic heart failure, and explore applications for second generation endothelin antagonists including TBC3711.
Both parties will equally fund the cost of research and development of sitaxsentan and second-generation endothelin antagonist compounds, commercialize resulting products, and share equally in the profits from this worldwide collaboration.
ICOS will make milestone payments to Texas Biotechnology that could be as much as $55.5 million for the development and commercialization of products resulting from the collaboration.
``The most compelling finding we saw with sitaxsentan was its ability to reduce pulmonary pressures without negatively affecting a patient`s heart rate or their systemic pressures,`` Dr. Wilson Colucci, professor of Medicine and Chief of Cardiovascular Medicine at Boston University and principal investigator for the Phase II chronic heart failure trial.
Hallo IWA Japan!
Nix für ungut aber geht es auch mal in Deutsch?
Nix für ungut aber geht es auch mal in Deutsch?
Infos sind halt eben in deutsch nicht verfügbar
Wer hat hier noochmal ein Übersetzungsprogramm?
nur soviel dazu, das wichtigste:
TXB entwicklet sein Phase II Präparat Sitaxsentan (s. oben) jetzt zusammen mit ICOS (entwicklen u.a. neues Potenzmittel, war auch schon 2 mal in der AKtionär) jetzt weiter. Es soll eine PhaseIIb/III Testreihe gestartet werden.
Hierbei erhält TXB bis zu 55,5 Mio $ an sogenannten Meilenstein-Zahlungen von Icos, falls vorher geplante Stufen der Entwicklung erreicht werden.
Zudem wird das MEdikament dann von beiden vermarktet (wenn es soweit kommt!)
Wer hat hier noochmal ein Übersetzungsprogramm?
nur soviel dazu, das wichtigste:
TXB entwicklet sein Phase II Präparat Sitaxsentan (s. oben) jetzt zusammen mit ICOS (entwicklen u.a. neues Potenzmittel, war auch schon 2 mal in der AKtionär) jetzt weiter. Es soll eine PhaseIIb/III Testreihe gestartet werden.
Hierbei erhält TXB bis zu 55,5 Mio $ an sogenannten Meilenstein-Zahlungen von Icos, falls vorher geplante Stufen der Entwicklung erreicht werden.
Zudem wird das MEdikament dann von beiden vermarktet (wenn es soweit kommt!)
hallo,
kann mir einer von euch einen guten biotech brief empfehlen, wenn möglich amerikanische. bin auf der suche, aber bis jetzt vergebens.
mfg
kann mir einer von euch einen guten biotech brief empfehlen, wenn möglich amerikanische. bin auf der suche, aber bis jetzt vergebens.
mfg
Nochmals hallo IWA Japan!
In welchen Bio-Tech Aktien bist du noch drin und wie siehst du diesen Run auf kleinere Biowerte?Habe zur Zeit nur Texas Biotech Creativ Biom.,Nanophase,versuche heute noch Sartoriius günstig zu bekommen.Bin bei den ersten drei gut gefahren diese Woche.Wie ist deine Einschätzung?
In welchen Bio-Tech Aktien bist du noch drin und wie siehst du diesen Run auf kleinere Biowerte?Habe zur Zeit nur Texas Biotech Creativ Biom.,Nanophase,versuche heute noch Sartoriius günstig zu bekommen.Bin bei den ersten drei gut gefahren diese Woche.Wie ist deine Einschätzung?
Guten Mittag an alle,
es kann doch nicht sein, dass keiner mir einen Biotech-Brief empfehlen kann. Habe gestern zwar einen amerik. gefunden, die haben aber technische Probleme auf ihrer Homepage. Ergo bin ich immer noch auf der Suche nach einem Brief.
Würde mich echt freuen, wenn sich einer die Mühe macht mir eine Empfehlung zu geben.
Also dann
es kann doch nicht sein, dass keiner mir einen Biotech-Brief empfehlen kann. Habe gestern zwar einen amerik. gefunden, die haben aber technische Probleme auf ihrer Homepage. Ergo bin ich immer noch auf der Suche nach einem Brief.
Würde mich echt freuen, wenn sich einer die Mühe macht mir eine Empfehlung zu geben.
Also dann
hi zyrtec@net,
kenne nur den biotech-report, weiß aber nicht, ob es den auch zum runterladen gibt. ansonsten empfiehlt auch der hot stock investor biotech aktien.
gruß
bug
kenne nur den biotech-report, weiß aber nicht, ob es den auch zum runterladen gibt. ansonsten empfiehlt auch der hot stock investor biotech aktien.
gruß
bug
Vielen Dank,
wenigstens hat sich einer gemeldet. Den kenne ich auch schon, da habe ich aber meine Zweifel ( aus Kulmbach ). Aber trotzdem Danke
wenigstens hat sich einer gemeldet. Den kenne ich auch schon, da habe ich aber meine Zweifel ( aus Kulmbach ). Aber trotzdem Danke
Kein Diskusionen mehr bei Texas?????
Der aufwärts Trend ist auf jeden Fall noch voll intakt und ich denke wenn der Widerstand bei 19,50-20E gebrochen wird geht es noch ein gutes Stück weiter nach oben!
Der aufwärts Trend ist auf jeden Fall noch voll intakt und ich denke wenn der Widerstand bei 19,50-20E gebrochen wird geht es noch ein gutes Stück weiter nach oben!
Hallo Zusammen,
die Kursentwicklung läßt die letzten Tage sehr zu wünschen übrig, hat jemand News, die diesen Absturz gerechtfertigt erscheinen lassen, danke für Eure Hilfe.
Gruss
Kawasuki
die Kursentwicklung läßt die letzten Tage sehr zu wünschen übrig, hat jemand News, die diesen Absturz gerechtfertigt erscheinen lassen, danke für Eure Hilfe.
Gruss
Kawasuki
Hallo Zusammen,
Texas scheint etwas in Vergessenheit zu geraten, habe nicht neues an Infos finden können, war jemand von Euch erfolgreicher? - Danke für Hinweise
Gruss
Kawasuki
Texas scheint etwas in Vergessenheit zu geraten, habe nicht neues an Infos finden können, war jemand von Euch erfolgreicher? - Danke für Hinweise
Gruss
Kawasuki
Friday June 30, 12:23 pm Eastern Time
Company Press Release
SOURCE: SmithKline Beecham; Texas Biotechnology Corporation
SmithKline Beecham and Texas Biotechnology Announce Argatroban`s Approval For The Prevention or Treatment of Thrombosis in Heparin-Induced Thrombocytopenia
New Drug Offers Safe and Effective Treatment Option for Potentially Fatal Disorder
PHILADELPHIA, June 30 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH - news) and Texas Biotechnology Corporation (Amex: TXB - news) today announced the U.S. Food and Drug Administration`s (FDA) approval of the anticoagulant argatroban for the prevention or treatment of thrombosis (abnormal blood clotting) associated with heparin-induced thrombocytopenia (HIT). HIT is a serious immune disorder caused by heparin, a common anticoagulant used to prevent blood clots. Each year, nearly 12 million Americans are treated with heparin for conditions such as blood clots in the legs or lungs, heart attacks, or angioplasty. Of these 12 million people, as many as 360,000 will develop HIT, an estimated 120,000 will develop a thrombotic complication (stroke, limb amputation, or death), and up to 36,000 will die.
Argatroban blocks the activity of thrombin, a key factor in blood clotting. It is the first synthetic direct thrombin inhibitor approved for the prevention and treatment of thrombosis in patients with HIT. Argatroban was developed by Texas Biotechnology Corporation (TBC). Under an agreement with TBC, SmithKline Beecham has the rights to market and co-develop argatroban in the U.S. and Canada.
``The availability of a new anticoagulant such as argatroban to treat HIT patients who are at high risk for developing thrombosis and other potentially life threatening complications is good news for physicians and patients, since safe and effective treatments have been limited,`` said John Kelton, professor and chairman, department of medicine, McMaster University, Ontario, Canada. ``This patient population has historically been very difficult to treat because of the lack of good treatments. In clinical trials, argatroban offered fast acting clinical efficacy without significant risk factors and provided easy monitoring.``
The HIT Paradox
Heparin is one of the most commonly used medications in U.S. hospitals. However, heparin therapy can cause an immune-disorder known as HIT, which is clinically diagnosed by a drop in blood platelet count below 100,000/microliter or a dramatic 50 percent reduction in platelet count, as compared to baseline. Although heparin is administered to prevent blood clots, in HIT patients it may paradoxically result in the development of blood clots.
HIT usually occurs five to 10 days following heparin treatment, although it may begin sooner. Diagnosis of the disorder can be complicated by similarities between the symptoms of HIT and other syndromes, as well as the limitations of existing laboratory assays. Diagnosis can be made even more challenging because physicians expect bleeding, not clotting, with thrombocytopenia (abnormally low platelet count). Thus, physicians may inadvertently exacerbate the condition by continuing anticoagulation therapy with heparin in patients who develop HIT.
If left untreated or misdiagnosed, HIT patients may develop serious complications such as pulmonary embolism (blood clot in the lungs), heart attack, limb damage requiring amputation, or even death. Mortality from HIT is estimated to be as high as 30 percent in patients who develop serious complications.
Argatroban Safe and Effective for Treatment or Prevention of Thrombosis in
HIT
Argatroban`s safety and efficacy were demonstrated in two multicenter, prospective, open-label, historically-controlled, clinical trials. The studies involved 568 argatroban-treated patients and 193 historical controls. Patients enrolled had a clinical diagnosis of heparin-induced thrombocytopenia, either with or without thrombosis. Thrombocytopenia was defined as a fall in platelet count to less than 100,000/microliter or a 50 percent decrease in platelets after heparin therapy was started. Researchers evaluated clinical outcomes, including death, amputation, or new thrombosis during the treatment and follow-up period.
Argatroban significantly improved clinical outcomes for patients with HIT. In trials in which outcomes were monitored over 37 days, the composite of death, amputation or new thrombosis occurred in 34% of the 568 argatroban-treated patients compared with 43% of the 193 historical controls. Therefore, argatroban therapy provided a 21 percent relative reduction in the risk of death, amputation or new thrombosis -- and delayed the onset of these events. Furthermore, argatroban provided significantly faster platelet count recovery. Argatroban also resulted in adequate anticoagulation in more than 75 percent of patients within 3-5 hours of the initiation of therapy. These benefits were realized without increased bleeding risk compared with controls.
``We are excited that argatroban will soon be available to the medical community for the many patients administered heparin each year who develop HIT,`` said David Stout, SmithKline Beecham`s President of Pharmaceuticals-N.A. ``Importantly, argatroban offers distinct advantages over other available anticoagulants in terms of predictable response, rapid onset of action, no cross-reactivity, and no dose adjustment in patients with impaired kidney function.``
Bleeding is a serious concern associated with anticoagulation therapy. Major bleeding events observed with argatroban-treated patients included gastrointestinal (2.3 percent vs. 1.6 percent for the control group) and genitourinary (0.9 percent vs. 0.5 percent for the control group). Intracranial bleeding was not observed in the 568 patients treated with argatroban. As with any anticoagulation therapy, argatroban is contraindicated in patients with overt major bleeding or in patients hypersensitive to the product or any of its components.
SmithKline Beecham -- one of the world`s leading healthcare companies -- discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products. For company information, visit SmithKline Beecham on the World Wide Web at http://www.sb.com.
Texas Biotechnology is a biopharmaceutical company focused on the development and commercialization of small molecule drugs to treat a variety of diseases including thrombosis, pulmonary hypertension, heart failure, and asthma. For company information, visit TBC on the World Wide Web at http://www.tbc.com.
SOURCE: SmithKline Beecham; Texas Biotechnology Corporation
Company Press Release
SOURCE: SmithKline Beecham; Texas Biotechnology Corporation
SmithKline Beecham and Texas Biotechnology Announce Argatroban`s Approval For The Prevention or Treatment of Thrombosis in Heparin-Induced Thrombocytopenia
New Drug Offers Safe and Effective Treatment Option for Potentially Fatal Disorder
PHILADELPHIA, June 30 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH - news) and Texas Biotechnology Corporation (Amex: TXB - news) today announced the U.S. Food and Drug Administration`s (FDA) approval of the anticoagulant argatroban for the prevention or treatment of thrombosis (abnormal blood clotting) associated with heparin-induced thrombocytopenia (HIT). HIT is a serious immune disorder caused by heparin, a common anticoagulant used to prevent blood clots. Each year, nearly 12 million Americans are treated with heparin for conditions such as blood clots in the legs or lungs, heart attacks, or angioplasty. Of these 12 million people, as many as 360,000 will develop HIT, an estimated 120,000 will develop a thrombotic complication (stroke, limb amputation, or death), and up to 36,000 will die.
Argatroban blocks the activity of thrombin, a key factor in blood clotting. It is the first synthetic direct thrombin inhibitor approved for the prevention and treatment of thrombosis in patients with HIT. Argatroban was developed by Texas Biotechnology Corporation (TBC). Under an agreement with TBC, SmithKline Beecham has the rights to market and co-develop argatroban in the U.S. and Canada.
``The availability of a new anticoagulant such as argatroban to treat HIT patients who are at high risk for developing thrombosis and other potentially life threatening complications is good news for physicians and patients, since safe and effective treatments have been limited,`` said John Kelton, professor and chairman, department of medicine, McMaster University, Ontario, Canada. ``This patient population has historically been very difficult to treat because of the lack of good treatments. In clinical trials, argatroban offered fast acting clinical efficacy without significant risk factors and provided easy monitoring.``
The HIT Paradox
Heparin is one of the most commonly used medications in U.S. hospitals. However, heparin therapy can cause an immune-disorder known as HIT, which is clinically diagnosed by a drop in blood platelet count below 100,000/microliter or a dramatic 50 percent reduction in platelet count, as compared to baseline. Although heparin is administered to prevent blood clots, in HIT patients it may paradoxically result in the development of blood clots.
HIT usually occurs five to 10 days following heparin treatment, although it may begin sooner. Diagnosis of the disorder can be complicated by similarities between the symptoms of HIT and other syndromes, as well as the limitations of existing laboratory assays. Diagnosis can be made even more challenging because physicians expect bleeding, not clotting, with thrombocytopenia (abnormally low platelet count). Thus, physicians may inadvertently exacerbate the condition by continuing anticoagulation therapy with heparin in patients who develop HIT.
If left untreated or misdiagnosed, HIT patients may develop serious complications such as pulmonary embolism (blood clot in the lungs), heart attack, limb damage requiring amputation, or even death. Mortality from HIT is estimated to be as high as 30 percent in patients who develop serious complications.
Argatroban Safe and Effective for Treatment or Prevention of Thrombosis in
HIT
Argatroban`s safety and efficacy were demonstrated in two multicenter, prospective, open-label, historically-controlled, clinical trials. The studies involved 568 argatroban-treated patients and 193 historical controls. Patients enrolled had a clinical diagnosis of heparin-induced thrombocytopenia, either with or without thrombosis. Thrombocytopenia was defined as a fall in platelet count to less than 100,000/microliter or a 50 percent decrease in platelets after heparin therapy was started. Researchers evaluated clinical outcomes, including death, amputation, or new thrombosis during the treatment and follow-up period.
Argatroban significantly improved clinical outcomes for patients with HIT. In trials in which outcomes were monitored over 37 days, the composite of death, amputation or new thrombosis occurred in 34% of the 568 argatroban-treated patients compared with 43% of the 193 historical controls. Therefore, argatroban therapy provided a 21 percent relative reduction in the risk of death, amputation or new thrombosis -- and delayed the onset of these events. Furthermore, argatroban provided significantly faster platelet count recovery. Argatroban also resulted in adequate anticoagulation in more than 75 percent of patients within 3-5 hours of the initiation of therapy. These benefits were realized without increased bleeding risk compared with controls.
``We are excited that argatroban will soon be available to the medical community for the many patients administered heparin each year who develop HIT,`` said David Stout, SmithKline Beecham`s President of Pharmaceuticals-N.A. ``Importantly, argatroban offers distinct advantages over other available anticoagulants in terms of predictable response, rapid onset of action, no cross-reactivity, and no dose adjustment in patients with impaired kidney function.``
Bleeding is a serious concern associated with anticoagulation therapy. Major bleeding events observed with argatroban-treated patients included gastrointestinal (2.3 percent vs. 1.6 percent for the control group) and genitourinary (0.9 percent vs. 0.5 percent for the control group). Intracranial bleeding was not observed in the 568 patients treated with argatroban. As with any anticoagulation therapy, argatroban is contraindicated in patients with overt major bleeding or in patients hypersensitive to the product or any of its components.
SmithKline Beecham -- one of the world`s leading healthcare companies -- discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products. For company information, visit SmithKline Beecham on the World Wide Web at http://www.sb.com.
Texas Biotechnology is a biopharmaceutical company focused on the development and commercialization of small molecule drugs to treat a variety of diseases including thrombosis, pulmonary hypertension, heart failure, and asthma. For company information, visit TBC on the World Wide Web at http://www.tbc.com.
SOURCE: SmithKline Beecham; Texas Biotechnology Corporation
Tuesday August 1, 8:03 am Eastern Time
Press Release
SOURCE: Texas Biotechnology Corporation
Texas Biotechnology Announces Initial Financing of Majority-Owned German Subsidiary
Funding Expected to Total Up to DM 30 Million; TBC Retains North American Rights to Selectin Antagonist in Phase II
HOUSTON, Aug. 1 /PRNewswire/ -- Texas Biotechnology Corporation (Amex: TXB - news) today announced initial financing of its majority-owned German subsidiary, Revotar Biopharmaceuticals AG, with equity investments by German venture capital firms bmp AG and Mediport AG.
Based in the Berlin-Brandenburg area, Revotar Biopharmaceuticals is focused on the discovery and development of small molecule drugs to treat inflammatory diseases, including asthma and psoriasis.
Revotar`s lead product, TBC1269, is a novel selectin antagonist in Phase II clinical trials for treating asthma. Revotar will also have access to Texas Biotechnology`s unique drug discovery technologies, including several early stage inflammatory programs.
Revotar raised DM 10 million in equity thus far and has in place additional sources of non-dilutive funding through German government grants and loans, which are expected to increase total start-up funding up to DM 30 million. TBC owns 55.2% of Revotar which it obtained in exchange for technology contributed to the company. TBC has retained North American territorial rights to TBC1269, but all costs to develop the product for asthma and psoriasis will be borne by Revotar, which will have European rights.
Revotar`s management team and Board include Dr. Horst Witzel, former Chairman of the Board of Executive Directors of Schering AG; Dr. Karl-Gerhard Seifert of Deutsche Morgan Grenfell and formerly CEO of Clariant AG; Dr. Rotraut Labs, former Executive Vice President and Head of Global Development, Hoechst Marion Roussel (now Aventis) and Dr. Rainer Zahlten, formerly Sr. Vice President and Head of Global Clinical Research and Development, Hoechst Marion Roussel.
``The caliber of the people we have attracted to Revotar reflects the tremendous promise of this venture,`` stated David B. McWilliams, President and Chief Executive Officer of Texas Biotechnology. ``Revotar provides a very effective way for us to accelerate the development of TBC1269 and allows us to expand TBC`s presence in Europe, where we believe the burgeoning capital markets and life science sector represent significant upside opportunities.``
The founding of Revotar was strongly supported by the Industrial Investment Council in Berlin, a government institution for promoting new business ventures in Germany (www.iic.de). Aqua Partners LLC of New York (www.aquapartners.com), an affiliate of Roberts Mitani, LLC of New York (www.robertsmitani.com), acted as financial advisors in this transaction.
Texas Biotechnology is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of a variety of conditions and serious diseases, including thrombosis, pulmonary hypertension, chronic heart failure, systemic hypertension, asthma and rheumatoid arthritis. Its lead drug, argatroban, recently received approval from the FDA. For company information, visit www.tbc.com.
This press release contains forward-looking information that is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are attainment of research and clinical goals of product candidates, attainment of required governmental approval and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission.
SOURCE: Texas Biotechnology Corporation
Press Release
SOURCE: Texas Biotechnology Corporation
Texas Biotechnology Announces Initial Financing of Majority-Owned German Subsidiary
Funding Expected to Total Up to DM 30 Million; TBC Retains North American Rights to Selectin Antagonist in Phase II
HOUSTON, Aug. 1 /PRNewswire/ -- Texas Biotechnology Corporation (Amex: TXB - news) today announced initial financing of its majority-owned German subsidiary, Revotar Biopharmaceuticals AG, with equity investments by German venture capital firms bmp AG and Mediport AG.
Based in the Berlin-Brandenburg area, Revotar Biopharmaceuticals is focused on the discovery and development of small molecule drugs to treat inflammatory diseases, including asthma and psoriasis.
Revotar`s lead product, TBC1269, is a novel selectin antagonist in Phase II clinical trials for treating asthma. Revotar will also have access to Texas Biotechnology`s unique drug discovery technologies, including several early stage inflammatory programs.
Revotar raised DM 10 million in equity thus far and has in place additional sources of non-dilutive funding through German government grants and loans, which are expected to increase total start-up funding up to DM 30 million. TBC owns 55.2% of Revotar which it obtained in exchange for technology contributed to the company. TBC has retained North American territorial rights to TBC1269, but all costs to develop the product for asthma and psoriasis will be borne by Revotar, which will have European rights.
Revotar`s management team and Board include Dr. Horst Witzel, former Chairman of the Board of Executive Directors of Schering AG; Dr. Karl-Gerhard Seifert of Deutsche Morgan Grenfell and formerly CEO of Clariant AG; Dr. Rotraut Labs, former Executive Vice President and Head of Global Development, Hoechst Marion Roussel (now Aventis) and Dr. Rainer Zahlten, formerly Sr. Vice President and Head of Global Clinical Research and Development, Hoechst Marion Roussel.
``The caliber of the people we have attracted to Revotar reflects the tremendous promise of this venture,`` stated David B. McWilliams, President and Chief Executive Officer of Texas Biotechnology. ``Revotar provides a very effective way for us to accelerate the development of TBC1269 and allows us to expand TBC`s presence in Europe, where we believe the burgeoning capital markets and life science sector represent significant upside opportunities.``
The founding of Revotar was strongly supported by the Industrial Investment Council in Berlin, a government institution for promoting new business ventures in Germany (www.iic.de). Aqua Partners LLC of New York (www.aquapartners.com), an affiliate of Roberts Mitani, LLC of New York (www.robertsmitani.com), acted as financial advisors in this transaction.
Texas Biotechnology is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of a variety of conditions and serious diseases, including thrombosis, pulmonary hypertension, chronic heart failure, systemic hypertension, asthma and rheumatoid arthritis. Its lead drug, argatroban, recently received approval from the FDA. For company information, visit www.tbc.com.
This press release contains forward-looking information that is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are attainment of research and clinical goals of product candidates, attainment of required governmental approval and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission.
SOURCE: Texas Biotechnology Corporation
halt! noch eine vergessen
Schering-Plough and Texas Biotechnology Form Alliance to Discover, Develop VLA-4 Antagonist Drugs to Treat Asthma
MADISON, N.J. and HOUSTON, July 10 /PRNewswire/ -- Schering-Plough
Corporation (NYSE: SGP) and Texas Biotechnology Corporation (Amex: TXB) today
announced a worldwide research collaboration and license agreement to
discover, develop and commercialize VLA-4 antagonists. VLA-4 antagonists
represent a new class of compounds that has shown promise in multiple
preclinical animal models of asthma. The primary focus of the collaboration
will be to discover orally available VLA-4 antagonists as treatments for
asthma.
Richard Dixon, Ph.D., chief scientific officer and senior vice president
of research, Texas Biotechnology, stated, "We believe the mechanism of action
of VLA-4 antagonists is unique and may represent a substantial improvement
over existing anti-asthma agents. We see this alliance with Schering-Plough,
a recognized expert in this therapeutic area, as an effective way to
accelerate our development timelines and validate the therapeutic and
commercial value of VLA-4 antagonists."
"Texas Biotechnology has successfully developed a highly potent series of
VLA-4 antagonist compounds that have demonstrated significant activity in
several well-accepted in vivo models involving lung inflammation," said
Jonathan R. Spicehandler, M.D., president of Schering-Plough Research
Institute. "We look forward to this collaboration with Texas Biotechnology
and are hopeful that these efforts will lead to important new therapies for
the treatment of asthma, a serious and life-threatening disease."
Under the terms of the agreement, Schering-Plough obtains the exclusive
worldwide rights to develop, manufacture and market all compounds from Texas
Biotechnology`s library of VLA-4 antagonists, as well as the rights to a
second integrin antagonist. Texas Biotechnology will be responsible for
optimizing a lead compound and additional follow-on compounds.
Schering-Plough will support research at Texas Biotechnology and will be
responsible for all costs associated with the worldwide product development
program and commercialization of the compound. In addition to research costs,
Schering-Plough will pay an upfront license fee, development milestones and
royalties on product sales resulting from the agreement. Total payments to
Texas Biotechnology for both programs, excluding royalties, could reach
$87 million.
VLA-4, also referred to as the integrin A4B1, (alpha 4 beta 1) plays a key
role in inflammation by binding to VCAM-1. VCAM-1, a member of the family of
proteins called cell adhesion molecules, are also known to be involved in the
inflammatory response and cause white blood cells to migrate to sites of
inflammation on the walls of blood vessels. VLA-4 is found on most types of
white blood cells. Texas Biotechnology scientists believe that by blocking
the action of certain cell adhesion molecules, in this case VCAM-1, the
company`s compounds may prevent inflammation in a highly specific manner.
Currently, more than 15 million people in the United States suffer from asthma
and more than $12 billion a year is spent to treat this condition. As most
drugs do not cure the underlying cause of the disease, there is a clear
medical need for more effective therapies.
Texas Biotechnology is a biopharmaceutical company focused on the
discovery, development and commercialization of small molecule drugs to treat
a variety of vascular diseases including thrombosis, pulmonary hypertension,
heart failure and asthma.
Schering-Plough Research Institute is the pharmaceutical research and
development arm of Schering-Plough, a research-based company engaged in the
discovery, development, manufacturing and marketing of pharmaceutical products
worldwide.
TEXAS BIOTECHNOLOGY CORPORATION FORWARD-LOOKING STATEMENT:
This press release contains forward-looking information that is subject to
certain risks, trends and uncertainties that could cause actual results to
differ materially from those projected. Among those risks, trends and
uncertainties are attainment of research and clinical goals of product
candidates, attainment of required governmental approval and availability of
financing and revenues sufficient to fund development of product candidates
and operations. In particular, careful consideration should be given to
cautionary statements made in the various reports Texas Biotechnology has
filed with the Securities and Exchange Commission.
SOURCE Schering-Plough Corporation and Texas Biotechnology Corporation
Schering-Plough and Texas Biotechnology Form Alliance to Discover, Develop VLA-4 Antagonist Drugs to Treat Asthma
MADISON, N.J. and HOUSTON, July 10 /PRNewswire/ -- Schering-Plough
Corporation (NYSE: SGP) and Texas Biotechnology Corporation (Amex: TXB) today
announced a worldwide research collaboration and license agreement to
discover, develop and commercialize VLA-4 antagonists. VLA-4 antagonists
represent a new class of compounds that has shown promise in multiple
preclinical animal models of asthma. The primary focus of the collaboration
will be to discover orally available VLA-4 antagonists as treatments for
asthma.
Richard Dixon, Ph.D., chief scientific officer and senior vice president
of research, Texas Biotechnology, stated, "We believe the mechanism of action
of VLA-4 antagonists is unique and may represent a substantial improvement
over existing anti-asthma agents. We see this alliance with Schering-Plough,
a recognized expert in this therapeutic area, as an effective way to
accelerate our development timelines and validate the therapeutic and
commercial value of VLA-4 antagonists."
"Texas Biotechnology has successfully developed a highly potent series of
VLA-4 antagonist compounds that have demonstrated significant activity in
several well-accepted in vivo models involving lung inflammation," said
Jonathan R. Spicehandler, M.D., president of Schering-Plough Research
Institute. "We look forward to this collaboration with Texas Biotechnology
and are hopeful that these efforts will lead to important new therapies for
the treatment of asthma, a serious and life-threatening disease."
Under the terms of the agreement, Schering-Plough obtains the exclusive
worldwide rights to develop, manufacture and market all compounds from Texas
Biotechnology`s library of VLA-4 antagonists, as well as the rights to a
second integrin antagonist. Texas Biotechnology will be responsible for
optimizing a lead compound and additional follow-on compounds.
Schering-Plough will support research at Texas Biotechnology and will be
responsible for all costs associated with the worldwide product development
program and commercialization of the compound. In addition to research costs,
Schering-Plough will pay an upfront license fee, development milestones and
royalties on product sales resulting from the agreement. Total payments to
Texas Biotechnology for both programs, excluding royalties, could reach
$87 million.
VLA-4, also referred to as the integrin A4B1, (alpha 4 beta 1) plays a key
role in inflammation by binding to VCAM-1. VCAM-1, a member of the family of
proteins called cell adhesion molecules, are also known to be involved in the
inflammatory response and cause white blood cells to migrate to sites of
inflammation on the walls of blood vessels. VLA-4 is found on most types of
white blood cells. Texas Biotechnology scientists believe that by blocking
the action of certain cell adhesion molecules, in this case VCAM-1, the
company`s compounds may prevent inflammation in a highly specific manner.
Currently, more than 15 million people in the United States suffer from asthma
and more than $12 billion a year is spent to treat this condition. As most
drugs do not cure the underlying cause of the disease, there is a clear
medical need for more effective therapies.
Texas Biotechnology is a biopharmaceutical company focused on the
discovery, development and commercialization of small molecule drugs to treat
a variety of vascular diseases including thrombosis, pulmonary hypertension,
heart failure and asthma.
Schering-Plough Research Institute is the pharmaceutical research and
development arm of Schering-Plough, a research-based company engaged in the
discovery, development, manufacturing and marketing of pharmaceutical products
worldwide.
TEXAS BIOTECHNOLOGY CORPORATION FORWARD-LOOKING STATEMENT:
This press release contains forward-looking information that is subject to
certain risks, trends and uncertainties that could cause actual results to
differ materially from those projected. Among those risks, trends and
uncertainties are attainment of research and clinical goals of product
candidates, attainment of required governmental approval and availability of
financing and revenues sufficient to fund development of product candidates
and operations. In particular, careful consideration should be given to
cautionary statements made in the various reports Texas Biotechnology has
filed with the Securities and Exchange Commission.
SOURCE Schering-Plough Corporation and Texas Biotechnology Corporation
Princeton, New Jersey, July 10 (Bloomberg Data) -- Texas Biotech Corp. (TXB US) was reiterated ``buy`` [/b9by analyst Elise T Wang at PaineWebber Inc. The 12-month target price is $35.00 per share.
Princeton, New Jersey, June 22 (Bloomberg Data) -- Texas Biotech Corp. (TXB US) was rated new ``strong buy`` in new coverage by analyst Albert L Rauch at First Union Securities Inc. The target price is $30 per share.
Princeton, New Jersey, June 22 (Bloomberg Data) -- Texas Biotech Corp. (TXB US) was rated new ``strong buy`` in new coverage by analyst Albert L Rauch at First Union Securities Inc. The target price is $30 per share.
Hallo IWA Japan,
Tanks a lot for this great informations, da kann man sich eigentlich beruhigt zurücklehnen und die weitere Kursentwicklung, welche sicherlich positiv aussehen dürfte verfolgen. Danke nochmal
Gruss aus Indien
Kawasuki
Tanks a lot for this great informations, da kann man sich eigentlich beruhigt zurücklehnen und die weitere Kursentwicklung, welche sicherlich positiv aussehen dürfte verfolgen. Danke nochmal
Gruss aus Indien
Kawasuki
bist du Inder oder nur dort im Urlaub?
oder nach Indien ausgewandert
oder nach Indien ausgewandert
Hallo IWA Japan,
bin Münchner und im Tourismusbereich tätig, wir ziehen in Goa gerade eine Infrastruktur für den europäischen Mittelstand hoch, die Blumenkinder haben sich bereits vor Jahren verabschiedet (no dope no hope), damit wurde der Weg frei für den Pauschaltouristen, welcher aber auch was geboten bekommen möchte.
Gruss und Danke nochmal
Kawasuki
bin Münchner und im Tourismusbereich tätig, wir ziehen in Goa gerade eine Infrastruktur für den europäischen Mittelstand hoch, die Blumenkinder haben sich bereits vor Jahren verabschiedet (no dope no hope), damit wurde der Weg frei für den Pauschaltouristen, welcher aber auch was geboten bekommen möchte.
Gruss und Danke nochmal
Kawasuki
Second Quarter Results
In the second quarter of 2000, TBC reported net income of $6.0 million, or $0.15 basic and $0.14 diluted per share, compared to a net loss of $3.9 million, or $0.11 basic and diluted per share, in the second quarter of 1999.
Revenues for the second quarter of 2000 totaled $11.2 million compared to $0.5 million for the second quarter of 1999. The increase in revenues for the current period was primarily due to the receipt of a $7.5 million milestone payment from SmithKline Beecham (SB) for the final approval of argatroban. SB is TBC`s marketing and manufacturing partner for argatroban in the U.S. and Canada. In addition, revenues in 2000 include an upfront payment related to a license agreement with Schering-Plough and revenue recognized from the ICOS- TBC partnership. Net income for the quarter is primarily a result of revenues for the milestone payment from SB and the upfront payment from Schering- Plough.
Total operating expenses were $5.8 million for the second quarter of 2000, compared to $4.7 million for the same quarter of 1999. Research and development expense totaled $4.4 million during the second quarter of 2000 compared to $3.1 million in the second quarter of 1999. The increase was due primarily to increases in research and development expenses for sitaxsentan and a $1.0 million non-cash charge to in-process research and development related to the issuance of common stock for the license for argatroban. General and administrative expenses totaled $1.4 million in the second quarter compared to $1.6 million in the second quarter of 1999.
During the second quarter of 2000, the Company recognized $0.6 million of losses related to its equity interest in the ICOS-TBC partnership.
Investment income totaled $1.1 million for the first quarter of 2000 compared to $0.3 million in the first quarter of 1999. The increase was primarily due to an increase in invested funds, which included $65.2 million raised in a public offering of common stock in April 2000.
First Half Results
In the first half of 2000, TBC reported net income of $1.0 million, or $0.03 basic and $0.02 diluted per share, compared to a net loss of $7.4 million, or $0.22 basic and diluted per share, in the first half of 1999.
Revenues for the first six months of 2000 were $11.8 million as compared to $1.0 million in the same period of 1999. The increase during 2000 was primarily due to the factors mentioned above. Net income for the first half is primarily a result of revenues for the milestone payment from SB and the upfront payment from Schering-Plough.
Total operating expenses were $11.5 million for the first half of 2000 as compared to $9.2 million in the same period of 1999. Research and development expense totaled $8.2 million as compared to $6.2 million for the same period of 1999. The increase was due primarily to a $1.0 million non-cash charge to in-process research and development related to the issuance of common stock for the license for argatroban and increases in scaleup and manufacturing costs related to the sitaxsentan program. General and administrative expenses totaled $3.4 million for the first half of 2000 compared to $2.9 million in the same period of 1999. The increase was due primarily to increases in premarketing and consulting costs related to argatroban.
During the first half of 2000, the Company recognized $0.6 million of losses related to its equity interest in the ICOS-TBC partnership.
Investment income totaled $1.3 million for the second half of 2000 compared to $0.7 million in the second half of 1999. The increase was primarily due to an increase in invested funds, which included $65.2 million raised in a public offering of common stock in April 2000.
Cash, cash equivalents, investments and interest receivable was $77.5 million at June 30, 2000 compared to $22.2 million at June 30, 1999. At July 31, 2000, the total was approximately $88.0 million.
David B. McWilliams, President and Chief Executive Officer of Texas Biotechnology stated, ``The accomplishments we have achieved during the past few months have fundamentally changed our Company. Through the approval of argatroban, the formation of several strategic and diversified alliances, and a healthy cash position, we are now in a much stronger position to move the Company towards profitability and build sustainable shareholder value.``
Argatroban Approved by U.S. Food & Drug Administration -- Milestone Payment of $7.5 million Received -- Product Launch Planned for September
On June 30, TBC announced that the U.S. Food & Drug Administration had formally approved argatroban as an anticoagulant for prophylaxis and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). The ability to use argatroban as a prevention as well as a treatment for HIT significantly expands the therapeutic and commercial value of the drug.
Since approval, scale-up processes for commercial manufacturing of argatroban has been completed and advertising and marketing plans have been activated in conjunction with additional market research. The product launch is planned for September and will be supported by symposia and medical education activities at several major scientific meetings during the next few months.
Major Alliance Established for Endothelin Antagonist Program -- Milestone Payments to Texas Biotechnology Could Total $55.5 million
On June 6, ICOS and Texas Biotechnology formed a partnership to share equally in the development and commercialization of TBC`s endothelin antagonists. The TBC/ICOS team`s immediate goal is the start of a Phase IIb/III clinical study of sitaxsentan, the lead candidate, as a treatment for pulmonary hypertension. This trial is scheduled to begin late this year or early next year and will be immediately followed by a second Phase III study in Europe. These trials are expected to provide the basis for a New Drug Application filing. Approval for this indication is likely to be the shortest route to market as there is a significant unmet medical need for a safe, well-tolerated and effective oral therapy for these patients.
The TBC/ICOS team is also planning to begin a Phase I trial for TBC3711 by year-end. TBC3711, a second generation endothelin antagonist, is a more selective and potentially more potent drug than sitaxsentan, and is expected to be developed as a treatment for chronic heart failure and/or hypertension.
Results from a 20 patient open-label Phase II pulmonary hypertension trial of sitaxsentan, as well as a 30 patient open-label Phase II hypertension study, have been submitted to the American Heart Association Scientific Meeting scheduled for November. Preliminary results for both of these completed trials were positive and support ongoing development of sitaxsentan as an oral treatment for pulmonary hypertension.
VLA-4 Program Licensed to Schering-Plough -- Total Payments to Texas Biotechnology, Excluding Royalties, Could Reach $87 million
On July 10, TBC announced it established a worldwide research collaboration and license agreement with Schering-Plough to develop and commercialize VLA-4 antagonists. The primary focus of the collaboration is the development of orally-available VLA-4 antagonists as treatments for asthma.
Under the terms of the agreement, Schering-Plough obtains the exclusive worldwide rights to develop, manufacture and market all compounds from TBC`s library of VLA-4 antagonists, as well as the rights to a second integrin antagonist. TBC will be responsible for optimizing a lead compound and additional follow-on compounds. Schering-Plough will support research at TBC and will be responsible for all costs associated with the worldwide product development program and commercialization of the compound. In addition to paying research costs, Schering-Plough has paid an upfront license fee, and will pay development milestones and royalties on product sales resulting from the agreement.
Schering-Plough, a recognized expert in this therapeutic area, represents an effective way for Texas Biotechnology to validate the therapeutic and commercial value of this early stage research program and significantly accelerate our development timelines.
TBC1269 Licensed to Revotar Biopharmaceutical AG -- A Newly Formed Subsidiary with an Initial Funding up to DM 30 million
On August 1, TBC announced initial financing of a German subsidiary, Revotar Biopharmaceuticals AG. Texas Biotechnology owns 55.2% of Revotar as a result of licensing its targeted drug development technology platform and TBC1269, a novel selectin antagonist in Phase II development for asthma. While Revotar will be responsible for all costs to develop the product for asthma and psoriasis and will have all European rights, Texas Biotechnology has retained North American territorial rights to TBC1269.
Revotar`s immediate goals are to initiate a Phase I trial for TBC1269 using the inhaled formulation of the drug, followed immediately by a rigorous double-blind, placebo-controlled Phase II trial. During the next several months, TBC will be working closely with Revotar`s management team to establish a core R&D group that will focus on the discovery and development of new drug candidates from several early stage inflammatory programs at Texas Biotechnology.
Richard A.F. Dixon, Ph.D., Senior Vice President and Chief Scientific Officer of Texas Biotechnology stated, ``As proper utilization of our scientific and financial resources remains one of our highest priorities, it is rewarding to see so many of our lead programs validated and supported by partners with complimentary skills.``
Texas Biotechnology is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat a variety of vascular diseases including thrombosis, pulmonary hypertension, heart failure and asthma.
This press release contains forward-looking information that is subject to certain risks; trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are attainment of research and clinical goals of product candidates, attainment of required governmental approval and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission.
TEXAS BIOTECHNOLOGY CORPORATION
SELECTED FINANCIAL DATA
$ in thousands (except net income and (loss) per share)
Unaudited
Summary of Operations
Three months ended Six months ended
June 30, June 30,
2000 1999 2000 1999
Revenues $11,249 $495 $11,772 $1,030
Operating expenses:
Research and development 4,374 3,056 8,156 6,215
General and administrative 1,438 1,597 3,369 2,936
Equity in loss of affiliate (567) --- (567) ---
Investment income 1,128 302 1,331 687
Net income (loss) 5,998 (3,856) 1,011 (7,434)
Net Income (loss) per share:
Basic 0.15 (0.11) 0.03 (0.22)
Diluted 0.14 (0.11) 0.02 (0.22)
Weighted average shares used
to compute net income and (loss)
per share:
Basic 40,033 34,217 37,323 34,193
Diluted 43,261 34,217 40,693 34,193
Balance Sheets
June 30,
2000 1999
Cash and cash equivalents,
investments and accrued interest $77,540 $22,156
Total assets 91,650 28,572
Total liabilities 2,750 2,552
Stockholders` equity 88,900 26,020
At July 31, 2000 the Company had cash, cash equivalents, investments and accrued interest of approximately $88.0 million.
SOURCE: Texas Biotechnology Corporation
In the second quarter of 2000, TBC reported net income of $6.0 million, or $0.15 basic and $0.14 diluted per share, compared to a net loss of $3.9 million, or $0.11 basic and diluted per share, in the second quarter of 1999.
Revenues for the second quarter of 2000 totaled $11.2 million compared to $0.5 million for the second quarter of 1999. The increase in revenues for the current period was primarily due to the receipt of a $7.5 million milestone payment from SmithKline Beecham (SB) for the final approval of argatroban. SB is TBC`s marketing and manufacturing partner for argatroban in the U.S. and Canada. In addition, revenues in 2000 include an upfront payment related to a license agreement with Schering-Plough and revenue recognized from the ICOS- TBC partnership. Net income for the quarter is primarily a result of revenues for the milestone payment from SB and the upfront payment from Schering- Plough.
Total operating expenses were $5.8 million for the second quarter of 2000, compared to $4.7 million for the same quarter of 1999. Research and development expense totaled $4.4 million during the second quarter of 2000 compared to $3.1 million in the second quarter of 1999. The increase was due primarily to increases in research and development expenses for sitaxsentan and a $1.0 million non-cash charge to in-process research and development related to the issuance of common stock for the license for argatroban. General and administrative expenses totaled $1.4 million in the second quarter compared to $1.6 million in the second quarter of 1999.
During the second quarter of 2000, the Company recognized $0.6 million of losses related to its equity interest in the ICOS-TBC partnership.
Investment income totaled $1.1 million for the first quarter of 2000 compared to $0.3 million in the first quarter of 1999. The increase was primarily due to an increase in invested funds, which included $65.2 million raised in a public offering of common stock in April 2000.
First Half Results
In the first half of 2000, TBC reported net income of $1.0 million, or $0.03 basic and $0.02 diluted per share, compared to a net loss of $7.4 million, or $0.22 basic and diluted per share, in the first half of 1999.
Revenues for the first six months of 2000 were $11.8 million as compared to $1.0 million in the same period of 1999. The increase during 2000 was primarily due to the factors mentioned above. Net income for the first half is primarily a result of revenues for the milestone payment from SB and the upfront payment from Schering-Plough.
Total operating expenses were $11.5 million for the first half of 2000 as compared to $9.2 million in the same period of 1999. Research and development expense totaled $8.2 million as compared to $6.2 million for the same period of 1999. The increase was due primarily to a $1.0 million non-cash charge to in-process research and development related to the issuance of common stock for the license for argatroban and increases in scaleup and manufacturing costs related to the sitaxsentan program. General and administrative expenses totaled $3.4 million for the first half of 2000 compared to $2.9 million in the same period of 1999. The increase was due primarily to increases in premarketing and consulting costs related to argatroban.
During the first half of 2000, the Company recognized $0.6 million of losses related to its equity interest in the ICOS-TBC partnership.
Investment income totaled $1.3 million for the second half of 2000 compared to $0.7 million in the second half of 1999. The increase was primarily due to an increase in invested funds, which included $65.2 million raised in a public offering of common stock in April 2000.
Cash, cash equivalents, investments and interest receivable was $77.5 million at June 30, 2000 compared to $22.2 million at June 30, 1999. At July 31, 2000, the total was approximately $88.0 million.
David B. McWilliams, President and Chief Executive Officer of Texas Biotechnology stated, ``The accomplishments we have achieved during the past few months have fundamentally changed our Company. Through the approval of argatroban, the formation of several strategic and diversified alliances, and a healthy cash position, we are now in a much stronger position to move the Company towards profitability and build sustainable shareholder value.``
Argatroban Approved by U.S. Food & Drug Administration -- Milestone Payment of $7.5 million Received -- Product Launch Planned for September
On June 30, TBC announced that the U.S. Food & Drug Administration had formally approved argatroban as an anticoagulant for prophylaxis and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). The ability to use argatroban as a prevention as well as a treatment for HIT significantly expands the therapeutic and commercial value of the drug.
Since approval, scale-up processes for commercial manufacturing of argatroban has been completed and advertising and marketing plans have been activated in conjunction with additional market research. The product launch is planned for September and will be supported by symposia and medical education activities at several major scientific meetings during the next few months.
Major Alliance Established for Endothelin Antagonist Program -- Milestone Payments to Texas Biotechnology Could Total $55.5 million
On June 6, ICOS and Texas Biotechnology formed a partnership to share equally in the development and commercialization of TBC`s endothelin antagonists. The TBC/ICOS team`s immediate goal is the start of a Phase IIb/III clinical study of sitaxsentan, the lead candidate, as a treatment for pulmonary hypertension. This trial is scheduled to begin late this year or early next year and will be immediately followed by a second Phase III study in Europe. These trials are expected to provide the basis for a New Drug Application filing. Approval for this indication is likely to be the shortest route to market as there is a significant unmet medical need for a safe, well-tolerated and effective oral therapy for these patients.
The TBC/ICOS team is also planning to begin a Phase I trial for TBC3711 by year-end. TBC3711, a second generation endothelin antagonist, is a more selective and potentially more potent drug than sitaxsentan, and is expected to be developed as a treatment for chronic heart failure and/or hypertension.
Results from a 20 patient open-label Phase II pulmonary hypertension trial of sitaxsentan, as well as a 30 patient open-label Phase II hypertension study, have been submitted to the American Heart Association Scientific Meeting scheduled for November. Preliminary results for both of these completed trials were positive and support ongoing development of sitaxsentan as an oral treatment for pulmonary hypertension.
VLA-4 Program Licensed to Schering-Plough -- Total Payments to Texas Biotechnology, Excluding Royalties, Could Reach $87 million
On July 10, TBC announced it established a worldwide research collaboration and license agreement with Schering-Plough to develop and commercialize VLA-4 antagonists. The primary focus of the collaboration is the development of orally-available VLA-4 antagonists as treatments for asthma.
Under the terms of the agreement, Schering-Plough obtains the exclusive worldwide rights to develop, manufacture and market all compounds from TBC`s library of VLA-4 antagonists, as well as the rights to a second integrin antagonist. TBC will be responsible for optimizing a lead compound and additional follow-on compounds. Schering-Plough will support research at TBC and will be responsible for all costs associated with the worldwide product development program and commercialization of the compound. In addition to paying research costs, Schering-Plough has paid an upfront license fee, and will pay development milestones and royalties on product sales resulting from the agreement.
Schering-Plough, a recognized expert in this therapeutic area, represents an effective way for Texas Biotechnology to validate the therapeutic and commercial value of this early stage research program and significantly accelerate our development timelines.
TBC1269 Licensed to Revotar Biopharmaceutical AG -- A Newly Formed Subsidiary with an Initial Funding up to DM 30 million
On August 1, TBC announced initial financing of a German subsidiary, Revotar Biopharmaceuticals AG. Texas Biotechnology owns 55.2% of Revotar as a result of licensing its targeted drug development technology platform and TBC1269, a novel selectin antagonist in Phase II development for asthma. While Revotar will be responsible for all costs to develop the product for asthma and psoriasis and will have all European rights, Texas Biotechnology has retained North American territorial rights to TBC1269.
Revotar`s immediate goals are to initiate a Phase I trial for TBC1269 using the inhaled formulation of the drug, followed immediately by a rigorous double-blind, placebo-controlled Phase II trial. During the next several months, TBC will be working closely with Revotar`s management team to establish a core R&D group that will focus on the discovery and development of new drug candidates from several early stage inflammatory programs at Texas Biotechnology.
Richard A.F. Dixon, Ph.D., Senior Vice President and Chief Scientific Officer of Texas Biotechnology stated, ``As proper utilization of our scientific and financial resources remains one of our highest priorities, it is rewarding to see so many of our lead programs validated and supported by partners with complimentary skills.``
Texas Biotechnology is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat a variety of vascular diseases including thrombosis, pulmonary hypertension, heart failure and asthma.
This press release contains forward-looking information that is subject to certain risks; trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are attainment of research and clinical goals of product candidates, attainment of required governmental approval and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission.
TEXAS BIOTECHNOLOGY CORPORATION
SELECTED FINANCIAL DATA
$ in thousands (except net income and (loss) per share)
Unaudited
Summary of Operations
Three months ended Six months ended
June 30, June 30,
2000 1999 2000 1999
Revenues $11,249 $495 $11,772 $1,030
Operating expenses:
Research and development 4,374 3,056 8,156 6,215
General and administrative 1,438 1,597 3,369 2,936
Equity in loss of affiliate (567) --- (567) ---
Investment income 1,128 302 1,331 687
Net income (loss) 5,998 (3,856) 1,011 (7,434)
Net Income (loss) per share:
Basic 0.15 (0.11) 0.03 (0.22)
Diluted 0.14 (0.11) 0.02 (0.22)
Weighted average shares used
to compute net income and (loss)
per share:
Basic 40,033 34,217 37,323 34,193
Diluted 43,261 34,217 40,693 34,193
Balance Sheets
June 30,
2000 1999
Cash and cash equivalents,
investments and accrued interest $77,540 $22,156
Total assets 91,650 28,572
Total liabilities 2,750 2,552
Stockholders` equity 88,900 26,020
At July 31, 2000 the Company had cash, cash equivalents, investments and accrued interest of approximately $88.0 million.
SOURCE: Texas Biotechnology Corporation
hoffe, das es hier doch noch einige Interessenten gibt
IWA
IWA
im neuen finanzen (07/2001) zum Kauf empfohlen: Gute Pipeline, niedrige Marktkapitalisierung. Riskantes, aber chancenreiches Unternehmen.
interessant
hallo Texas-Rangers,
hier eine interessante Neuigkeit: TBX ist von der ASE in die Nasdaq gewechselt.
...sollte also auf jeder guten Watchlist stehen.
...Gruss Dr. Bust (DHI)
hier eine interessante Neuigkeit: TBX ist von der ASE in die Nasdaq gewechselt.
...sollte also auf jeder guten Watchlist stehen.
...Gruss Dr. Bust (DHI)
Hier ist ja gar nix mehr los.
Die letzten Tage habe ich ein paar TXBI eingesammelt. Am 25.10. sollen Zahlen kommen. Die Argatroban-Umsätze werden die Richtung für den Kurs bestimmen.
Die letzten Tage habe ich ein paar TXBI eingesammelt. Am 25.10. sollen Zahlen kommen. Die Argatroban-Umsätze werden die Richtung für den Kurs bestimmen.
Am 30.10. sollen die Zahlen kommen, nicht am 25.
Schlechte Umsätze mit Argatroban.
Gibt dickes Minus.
Gibt dickes Minus.
Der Kurseinbruch wg. des eher schlechten Argatroban-Absatzes war am 31.10. nur kurz & vorbörslich. Da A. bisher nur für einen kleinen Teil der möglichen Indikationen zugelassen ist, sollte die nächten Jahre weit mehr möglich sein.
Aktuell sieht es so aus, als kämen die Biotechs aus der 2. Reihe wieder etwas in Mode.
TXBI 6,50$ +0,88$ +15,66% 5,87 Mio. 22:00/16.11.
Aktuell sieht es so aus, als kämen die Biotechs aus der 2. Reihe wieder etwas in Mode.
TXBI 6,50$ +0,88$ +15,66% 5,87 Mio. 22:00/16.11.
Die Mädel von der FDA können ja doch zulassen 
Tuesday April 9, 8:18 am Eastern Time
GlaxoSmithKline, Texas Biotech Get FDA OK On Argatroban
(This story was originally published by Dow Jones Newswires)
HOUSTON -(Dow Jones)- Texas Biotechnlogy Corp.`s (TXBI) and GlaxoSmithKline Plc`s (GSK) Argatroban product received Food and Drug Administration approval to be an alternative anticoagulant drug for heart patients who are with or at risk for negative reactions to other anticoagulant, heparin.
In a press release Tuesday, the biotechnology and pharmaceutical companies said Argatroban is currently approved for prophylaxis or the treatment of thrombosis in patients with Heparin-induced thrombocytopenia, or HIT.
HIT is an immune-mediated response to heparin, the most widely-used anticoagulant used commonly in coronary procedures, which can lead to serious thrombotic complications and death.
Texas Biotechnology and GlaxoSmtihKline co -developed Argatroban with GlaxoSmithKline marketing it in the U.S.
Shares of Houston -based Texas Biotechnology`s shares closed Monday at $5.46, up 20 cents, or 3.8%, on the Nasdaq National Market. London -based Glaxosmithkline`s NYSE-listed stock closed at $46.51, down a penny.
Tuesday April 9, 8:18 am Eastern Time
GlaxoSmithKline, Texas Biotech Get FDA OK On Argatroban
(This story was originally published by Dow Jones Newswires)
HOUSTON -(Dow Jones)- Texas Biotechnlogy Corp.`s (TXBI) and GlaxoSmithKline Plc`s (GSK) Argatroban product received Food and Drug Administration approval to be an alternative anticoagulant drug for heart patients who are with or at risk for negative reactions to other anticoagulant, heparin.
In a press release Tuesday, the biotechnology and pharmaceutical companies said Argatroban is currently approved for prophylaxis or the treatment of thrombosis in patients with Heparin-induced thrombocytopenia, or HIT.
HIT is an immune-mediated response to heparin, the most widely-used anticoagulant used commonly in coronary procedures, which can lead to serious thrombotic complications and death.
Texas Biotechnology and GlaxoSmtihKline co -developed Argatroban with GlaxoSmithKline marketing it in the U.S.
Shares of Houston -based Texas Biotechnology`s shares closed Monday at $5.46, up 20 cents, or 3.8%, on the Nasdaq National Market. London -based Glaxosmithkline`s NYSE-listed stock closed at $46.51, down a penny.
Der Rebound eines exellent aufgestellten Biotech-Wertes hat begonnen. Bin ich der einzige hier, der die Situation ab heute so einschätzt ?!!
Gruß von callistephus
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 301 | ||
| 131 | ||
| 99 | ||
| 62 | ||
| 60 | ||
| 54 | ||
| 51 | ||
| 46 | ||
| 45 | ||
| 43 |
| Wertpapier | Beiträge | |
|---|---|---|
| 41 | ||
| 33 | ||
| 29 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 24 | ||
| 20 | ||
| 20 | ||
| 19 |
